Skip to main content
logo
Vertex Pharmaceuticals Incorporated (LON:0QZU)
London flag London · Delayed Price · Currency is GBP · Price in USD
476.44
-1.73 (-0.36%)
Mar 5, 2026, 1:36 PM GMT

Vertex Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
12,00111,0209,8698,9317,574
Revenue Growth (YoY)
8.90%11.66%10.51%17.91%22.06%
Cost of Revenue
1,6511,5311,2621,080904.2
Gross Profit
10,3509,4908,6077,8506,670
Selling, General & Admin
1,7531,4641,137944.7840.1
Research & Development
4,0438,2593,6902,6563,051
Other Operating Expenses
381.1-0.5-51.6-57.5-3.1
Operating Income
4,173-232.93,8324,3072,782
Interest Income
490.9598.1614.7144.64.9
Interest Expense
-13.3-30.6-44.1-54.8-61.5
Other Non-Operating Income (Expense)
-7.7-86.1-22.8-164.84.9
Total Non-Operating Income (Expense)
469.9481.4547.8-75-51.7
Pretax Income
4,643248.54,3804,2322,730
Provision for Income Taxes
690784.1760.2910.4388.3
Net Income
3,953-535.63,6203,3222,342
Net Income to Common
3,953-535.63,6203,3222,342
Net Income Growth
--8.96%41.84%-13.63%
Shares Outstanding (Basic)
256258258256258
Shares Outstanding (Diluted)
258258261259260
Shares Change (YoY)
0.04%-1.00%0.54%-0.31%-1.33%
EPS (Basic)
15.46-2.0814.0512.979.09
EPS (Diluted)
15.32-2.0813.8912.829.01
EPS Growth
--8.35%42.29%-12.44%
Free Cash Flow
3,194-790.33,3373,9252,409
Free Cash Flow Growth
---14.99%62.97%-19.55%
Free Cash Flow Per Share
12.38-3.0612.8115.159.27
Gross Margin
86.24%86.11%87.21%87.90%88.06%
Operating Margin
34.77%-2.11%38.83%48.23%36.73%
Profit Margin
32.94%-4.86%36.68%37.20%30.92%
FCF Margin
26.61%-7.17%33.81%43.95%31.80%
EBITDA
4,383-25.74,0134,4562,908
EBITDA Margin
36.52%-0.23%40.66%49.89%38.39%
EBIT
4,173-232.93,8324,3072,782
EBIT Margin
34.77%-2.11%38.83%48.23%36.73%
Effective Tax Rate
14.86%315.53%17.36%21.51%14.22%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.